Biologics

In the last 12 months, two orthobiologics companies have expanded their focus and rebranded.

HippoFi and Zimmer Biomet are partnering to develop and launch a novel synthetic biomaterial for bone growth.

A group of lawmakers wrote a letter to Robert Califf, MD, the U.S. FDA commissioner, pushing for stricter guidance for bone grafts in light of a recent spate of tuberculosis linked to orthopedic products.

The consensus on whether regenerative medicine is effective in sports medicine is still up in the air, according to Michael Ciccotti, MD, of Rothman Orthopaedic Institute in Philadelphia.

A Michigan woman died from tuberculosis linked to tainted bone graft, The Detroit News reported Aug, 18.

Aziyo Biologics is in talks to divest its orthopedic business, the company said Aug. 14.

Here are five developments in orthopedic regenerative medicine since July 11.

Orthopedic surgeon Ken Zaslav, MD, performed the first commercial case with CartiHeal's Agili-C in the U.S., the medtech company said July 26.

The CDC and FDA are investigating an outbreak of tuberculosis linked to recently recalled viable bone matrix material.

Ronald Hillock, MD, an adult joint reconstruction surgeon and musculoskeletal oncologist at Nevada Orthopedic & Spine Center in Las Vegas, connected with Becker's to answer, "Are orthobiologics overhyped?"